Study identification  (Include author, title, year of publication, journal title, pages)

Guideline topic:

Key Question No:

Before completing this checklist, consider:

• Is the paper a randomized controlled trial or a controlled clinical trial? If in doubt, check the study design algorithm available from SIGN and make sure you have the correct checklist. If it is a controlled clinical trial questions 1.2, 1.3, and 1.4 are not relevant, and the study cannot be rated higher than 1+
• Is the paper relevant to key question? Analyse using PICO (Patient or Population Intervention Comparison Outcome). IF NO REJECT (give reason below). IF YES complete the checklist.

Reason for rejection: Reason for rejection: 1. Paper not relevant to key question □   2. Other reason □  (please specify):

Checklist completed by:  

In a well conducted RCT study…

1.1

The study addresses an appropriate and clearly focused question.

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.2

The assignment of subjects to treatment groups is randomised

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.3

An adequate concealment method is used

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.4

Subjects and investigators are kept ‘blind’ about treatment allocation

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.5

The treatment and control groups are similar at the start of the trial

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.6

The only difference between groups is the treatment under investigation

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.7

All relevant outcomes are measured in a standard, valid and reliable way

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.8

What percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?

1.9

All the subjects are analysed in the groups to which they were randomly allocated (often referred to as intention to treat analysis)

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

1.10

Where the study is carried out at more than one site, results are comparable for all sites

Well covered
Adequately addressed
Poorly addressed

Not addressed
Not reported
Not applicable

Section 2:   OVERALL ASSESSMENT OF THE STUDY

2.1

2.2

Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention?

2.3

Are the results of this study directly applicable to the patient group targeted by this guideline?

2.4

Notes. Summarise the authors conclusions. Add any comments on your own assessment of the study, and the extent to which it answers your question.

The following section is provided for non-SIGN users of this checklist and is being developed to conform to the standards set by the Guidelines International Network Evidence Tables Working Group.
Members of SIGN guideline groups do not need to complete this section.

Section 3:   description OF THE STUDY
PLEASE PRINT CLEARLY

3.1

Do we know who the study was funded by?

□ Academic Institution  □ Healthcare Industry
□ Government  □ NGO  □ Public funds  □ Other

3.2

How many centres are patients recruited from?

3.3

From which countries are patients selected? (Select all those involved. Note additional countries after “Other”)

□ Scotland  □ UK  □ USA  □ Canada
□ Australia  □ New Zealand  □ France  □ Germany
□ Italy  □ Netherlands  □ Scandinavia  □ Spain
□ Other:

3.4

What is the social setting (ie type of environment in which they live) of patients in the study?

□  Urban  □ Rural  □ Mixed

3.5

What criteria are used to decide who should be INCLUDED in the study?

3.6

3.7

What intervention or risk factor is investigated in the study? (Include dosage where appropriate)

3.8

What comparisons are made in the study (ie what alternative treatments are used to compare the intervention with). Include dosage where appropriate.

3.9

What methods were used to randomize patients, blind patients or investigators, and to conceal the randomization process from investigators?

3.10

How long did the active phase of the study last?

3.11

How long were patients followed-up for, during and after the study?

3.12

List the key characteristics of the patient population. Note if there are any significant differences between different arms of the trial.

3.13

Record the basic data for each arm of the study. If there are more than four arms, note data for subsequent arms at the bottom of the page.

Arm 1:
Treatment:
Sample size:
No. analysed
With outcome:
Without outcome:

Arm 2:
Treatment:
Sample size:
No. analysed
With outcome:
Without outcome>
Primary outcome?

Arm 3:
Treatment:
Sample size:
No. analysed
With outcome:
Without outcome>
Primary outcome?

Arm 4:
Treatment:
Sample size:
No. analysed
With outcome:
Without outcome
Primary outcome?

3.14

Record the basic data for each IMPORTANT outcome in the study. If there are more than four, not data for additional outcomes at the bottom of the page.

Outcome 1:
Value:
Measure:
P value
Upper CI
Lower CI
Primary outcome?

Outcome 2:
Value:
Measure:
P value
Upper CI
Lower CI
Primary outcome?

Outcome 3:
Value:
Measure:
P value
Upper CI
Lower CI
Primary outcome?

Outcome 4:
Value:
Measure:
P value
Upper CI
Lower CI
Primary outcome?

3.15

Notes. Summarise the authors conclusions. Add any comments on your own assessment of the study, and the extent to which it answers your question. {Much of this is likely to be contributed by GDG members).